国际神经病学神经外科学杂志2024，Vol.51Issue(1)：90-94,5.DOI:10.16636/j.cnki.jinn.1673-2642.2024.01.016
替罗非班辅助血管内治疗急性缺血性脑卒中的疗效评估研究进展
Research advancers in the efficacy of tirofiban in assisting endovascular treatment of acute ischemic stroke
摘要
Abstract
Acute ischemic stroke(AIS)is a clinical syndrome of neurological impairment caused by cerebral ischemia and hypoxia,and antiplatelet therapy is the basis for the prevention and treatment of ischemic stroke.At present,endovascular treatment methods for AIS include mechanical thrombectomy,thrombus aspiration,intra-arterial thrombolysis,and stent implantation,which can effectively improve blood flow and clinical symptoms;however,endovascular treatment may damage vascular endothelial cells,leading to platelet aggregation and thrombosis.The use of antiplatelet agents in the perioperative period of endovascular therapy is a common treatment method to reduce the complications such as thrombosis,embolism,and ischemia during and after surgery.In recent years,the latest reports on the use of antiplatelet agents in the endovascular treatment of AIS,especially platelet glycoprotein(GP)Ⅱb/Ⅲa receptor antagonists,have given rise to promising prospects for the development of the endovascular treatment of AIS.There are currently three GP Ⅱb/Ⅲa inhibitors that have been released by the US Food and Drug Administration,i.e.,tirofiban,abciximab,and eptifibatide.Tirofiban is a GP Ⅱb/Ⅲa receptor antagonist mainly used in China,and since GP Ⅱb/Ⅲa receptor acts as the final pathway for platelet aggregation and thrombosis,its antagonist exerts an antiplatelet aggregation effect rapidly by directly binding to GP Ⅱb/Ⅲa receptor.As a novel antiplatelet drug,tirofiban has been basically used in cardiovascular diseases,but its application in cerebrovascular diseases is still in the exploratory stage,with controversies over its specific usage,dosage,and safety,and such use is off-label use.This article reviews the application of tirofiban in the endovascular treatment of AIS and related research advances.关键词
急性缺血性脑卒中/血管内治疗/血小板糖蛋白Ⅱb/Ⅲa受体抑制剂/替罗非班Key words
acute ischaemic stroke/endovascular treatment/platelet glycoprotein Ⅱb/Ⅲa receptor inhibitor/tirofiban分类
医药卫生引用本文复制引用
张莉,傅新民,智文虹,刘志广..替罗非班辅助血管内治疗急性缺血性脑卒中的疗效评估研究进展[J].国际神经病学神经外科学杂志,2024,51(1):90-94,5.基金项目
徐州市科技项目(KC21234). （KC21234）
